Stryker Expands in Spine with Surgical Dynamics

With so much interesting technology in the spine market today, valuations are sky high. Stryker's $135 million deal for Surgical Dynamics raises eyebrows for its low price. But if it isn't the boldest move in spine, Stryker's deal could very turn out to be a very good one, as the company gains an important foothold in the spinal cage market.

On the face of it, Stryker Corp. 's purchase of spinal cage company Surgical Dynamics Inc. doesn't seem all that impressive [See Deal]. After all, Surgical Dynamics has been on the market with no takers for years, almost since the day its parent United States Surgical (now a division of Tyco Healthcare Group ) was acquired by Tyco International Ltd. in 1998 [See Deal]. And certainly foremost among the concerns of any potential acquirers had to be both the patent litigation that Surgical Dynamics was facing and, more generally, the disappointing fall-off of the spinal cage market beginning in the late 1990s. Indeed, Stryker's purchase price of $135 million pales before the valuations put on other innovative spinal companies: one month after its IPO, Kyphon Inc. 's market cap stood at $650 million [See Deal], while Oratec Interventions Inc. fetched $310 million in its recent deal with Smith & Nephew PLC [See Deal].

But people close to this deal say it may turn out to be a much better deal for Stryker than...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By 

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.